Conquering Neuromyelitis Optica Through Early, Accurate Diagnosis and Novel Therapeutics
Please choose a module from the options below. To receive credit and a certificate, you must complete all of the modules in this activity.
Welcome to this Med-IQ Select on the diagnosis and treatment of neuromyelitis optica spectrum disorder (NMOSD). Med-IQ Select is a unique online educational offering that allows you to pick and choose the content you would like to view—in any order and at your convenience.
Time to complete: 18 minutes
Time to complete: 14 minutes
Animated Video: Mechanisms of Action of 3 Targeted Therapies
Time to complete: 21 minutes
Time to complete: 7 minutes
Complete all of the above modules to earn credit;
0 out of 4 modules complete
Jeffrey Bennett, MD, PhD
Gertrude Gilden Professor for Neurodegenerative Disease Research
Departments of Neurology and Ophthalmology
University of Colorado School of Medicine
Lori Pender, PharmD, MPH
Manager, Educational Strategy and Content
Laura Rafferty, ELS
Kathryn Schaefer, MSN, RN, CPHRM
Senior Manager, Accreditation and Compliance
East Lansing, MI
Stephanie Wenick, MPhil
Wenick Communications, LLC
Chevy Chase, MD
Upon completion, participants should be able to:
- Apply guideline criteria for the diagnosis of patients with NMOSD
- Explore the pathophysiology of NMOSD and the corresponding mechanisms of action of emerging targeted therapies
- Examine clinical evidence on the safety and efficacy of emerging therapies for reducing the risk of relapse in patients with NMOSD
This activity is intended for neurologists, ophthalmologists, family practice/internal medicine physicians, nurse practitioners, and physician assistants.
Statement of Need
NMOSD is a rare, demyelinating disorder of the central nervous system (CNS) that commonly targets the optic nerves and spinal cord, eventually leading to blindness, muscle weakness, and paralysis. Advances in the understanding of the autoimmune nature of the disease have led to the creation of criteria for facilitating early, accurate diagnosis, as well as the identification of several new targets for therapy. With the approval of the first therapy for NMOSD in 2019 and 2 others in late-stage clinical development, it is critical that clinicians who care for these patients build their awareness and foundational knowledge of this disease so that they are better able to diagnose it early and offer treatment proven to reduce the risk of disease relapse.
Provided by Med-IQ.
Med-IQ is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Med-IQ designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurse practitioners, physician assistants, and other healthcare professionals who successfully complete the activity will receive a Statement of Participation indicating the maximum credits available.
Medium/Method of Participation
This is a 1.0-credit CME activity. To receive credit, read the introductory CME material, complete all of the modules, and complete the evaluation, attestation, and post-test, answering at least 70% of the post-test questions correctly.
Initial Release Date: December 20, 2019
Expiration Date: December 19, 2020
Estimated Time to Complete This Activity: 1 hour
Med-IQ requires any person in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as those in any amount occurring within the past 12 months, including those of a spouse/life partner, that could create a conflict of interest (COI). Individuals who refuse to disclose will not be permitted to contribute to this CME activity in any way. Med-IQ has policies in place that will identify and resolve COIs prior to this educational activity. Med-IQ also requires faculty to disclose discussions of investigational products or unlabeled/unapproved uses of drugs or devices regulated by the US Food and Drug Administration.
The content of this activity has been peer reviewed and has been approved for compliance. The faculty and contributors have indicated the following financial relationships, which have been resolved through an established COI resolution process, and have stated that these reported relationships will not have any impact on their ability to give an unbiased presentation.
Jeffrey Bennett, MD, PhD
Consulting fees/advisory boards: Alexion Pharmaceuticals, Inc., Chugai Pharmaceutical Co. Ltd., Clene Nanomedicine, EMD Serono, Inc., Equillium, Inc., F. Hoffmann-La Roche Ltd., Frequency Therapeutics, Genentech, Viela Bio
Contracted research: Mallinckrodt Pharmaceuticals
The writer, peer reviewers, and activity planners have no financial relationships to disclose.
Statement of Evidence-Based Content
Educational activities that assist physicians in carrying out their professional responsibilities more effectively and efficiently are consistent with the ACCME definition of continuing medical education (CME). As an ACCME-accredited provider of CME, Med-IQ has a policy to review and ensure that all the content and any recommendations, treatments, and manners of practicing medicine in CME activities are scientifically based, valid, and relevant to the practice of medicine. Med-IQ is responsible for validating the content of the CME activities it provides. Specifically, (1) all recommendations addressing the medical care of patients must be based on evidence that is scientifically sound and recognized as such within the profession; (2) all scientific research referred to, reported, or used in CME in support or justification of a patient care recommendation must conform to generally accepted standards of experimental design, data collection, and analysis.
Med-IQ is not liable for any decision made or action taken in reliance upon the information provided through this activity.
For questions or comments about this activity, please contact Med-IQ. Call (toll-free) 866 858 7434 or email firstname.lastname@example.org.
Operating system - Med-IQ supports the following operating systems:
- Microsoft Windows supported by Microsoft
- Mac OS supported by Apple
Browsers - Med-IQ supports the current version of each browser listed below, plus two prior versions:
Microsoft Internet Explorer
- Microsoft Edge
Operating system - Med-IQ supports the current operating system, plus two prior releases:
- Android (eg, Samsung Galaxy)
- Apple (eg, iPhone/iPad)
Browsers - Med-IQ supports the default browser for the applicable operating system release, plus two prior releases:
- Android (Chrome)
- Apple (Safari)
Applications & Software
PDF Viewer - Adobe Acrobat Reader or Adobe Reader
Adobe Flash Player - Med-IQ supports the current version, plus two prior versions
For technical assistance, please refer to our Support Manual.
The information provided through this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.
Privacy & Confidentiality
Acknowledgment of Commercial Support
This activity is supported by an educational grant from Genentech.
© 2019 Med-IQ, Inc.
Unless otherwise indicated, photographed subjects who appear within the content of this activity or on artwork associated with this activity are models; they are not actual patients or doctors.